Hinge Health (NYSE:HNGE) Releases Earnings Results, Beats Estimates By $0.31 EPS

Hinge Health (NYSE:HNGE) released its quarterly earnings results on Tuesday. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.28 by $0.31, FiscalAI reports. Hinge Health had a net margin of 15.15% and a return on equity of 65.44%. The firm had revenue of $212.82 million during the quarter. During the same quarter last year, the company earned $0.59 EPS. The firm’s revenue for the quarter was up 53.0% compared to the same quarter last year.

Here are the key takeaways from Hinge Health’s conference call:

• Q2 results exceeded expectations: Revenue grew 53% year over year to $213 million, operating margin expanded to 29%, and free cash flow rose to $100 million, or a 47% margin.
• Hinge Health raised its 2026 outlook to $856 million–$860 million of revenue and $236 million–$244 million of operating income, driven primarily by stronger-than-expected enrollment yields.
• The company’s platform expansion is gaining traction, with its migraine program reaching more than 450 clients and five million covered lives; it also agreed to acquire Cylinder Health for $105 million to enter gastrointestinal care.
• Commercial momentum remains strong, including an enterprise win covering nearly 300,000 lives, SMB lives growth of more than 100% in the first half, and an opt-out partnership expected to add clients beginning in 2027.
• Cylinder is currently operating at a loss and will require product integration and investment over the next nine to 24 months, potentially pressuring near-term margins even though management expects it to approach Hinge’s profitability profile within one to two years.

Hinge Health Stock Down 1.0%

Shares of NYSE HNGE traded down $0.84 during midday trading on Thursday, hitting $79.95. The company had a trading volume of 1,754,129 shares, compared to its average volume of 1,518,853. Hinge Health has a twelve month low of $30.08 and a twelve month high of $91.50. The firm has a market capitalization of $6.19 billion, a price-to-earnings ratio of 62.46 and a beta of 1.30. The business has a 50-day simple moving average of $75.05 and a two-hundred day simple moving average of $54.43.

Hinge Health News Roundup

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Strong Q2 results: Hinge Health reported $212.8 million in revenue, up 53% year over year, and adjusted earnings of $0.59 per share. Results exceeded the consensus estimate cited by several reports, while management highlighted stronger member conversion, improved margins and more than tripled free cash flow. Hinge Health reports record second quarter 2026 financial results
• Positive Sentiment: Raised outlook: The company guided for third-quarter revenue of $223 million to $225 million, above the roughly $211 million analyst estimate, and forecast 2026 revenue of $856 million to $860 million. The outlook reinforces expectations for continued high growth. Hinge Health forecasts 2026 revenue
• Positive Sentiment: Expansion into gastrointestinal care: Hinge Health agreed to acquire Cylinder Health for $105 million in cash. Cylinder’s virtual digestive-health platform is expected to support a new GI Care Program alongside Hinge’s existing musculoskeletal and migraine offerings, broadening its addressable market ahead of a planned broader rollout in 2027. Hinge Health signs agreement to acquire Cylinder
• Positive Sentiment: More bullish analyst views: Wells Fargo raised its price target to $103, Citizens JMP to $107 and Needham to $97, with each maintaining a positive rating. The revisions reflect improved growth and earnings expectations.
• Neutral Sentiment: Key consideration: The Cylinder transaction requires a $105 million cash payment, creating near-term integration and execution risk. HNGE also trades at a relatively elevated valuation, making the stock sensitive to any slowdown in growth or disappointment with the GI launch.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company increased their target price on shares of Hinge Health from $90.00 to $103.00 and gave the stock an “overweight” rating in a research note on Wednesday. KeyCorp upped their price objective on Hinge Health from $90.00 to $125.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Robert W. Baird increased their price objective on Hinge Health from $55.00 to $65.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 17th. Zacks Research raised Hinge Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Finally, Royal Bank Of Canada raised their price objective on shares of Hinge Health from $75.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $98.64.

Insider Transactions at Hinge Health

In related news, Chairman Gabriel M.I. Mecklenburg sold 83,334 shares of Hinge Health stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $85.05, for a total transaction of $7,087,556.70. Following the completion of the transaction, the chairman directly owned 83,334 shares of the company’s stock, valued at approximately $7,087,556.70. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President James Pursley sold 33,000 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $69.31, for a total value of $2,287,230.00. Following the sale, the president owned 740,897 shares in the company, valued at approximately $51,351,571.07. The trade was a 4.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,721,100 shares of company stock valued at $288,210,699 in the last quarter. 18.92% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hinge Health

Several institutional investors and hedge funds have recently made changes to their positions in HNGE. Wells Fargo & Company MN raised its position in Hinge Health by 160.0% during the fourth quarter. Wells Fargo & Company MN now owns 546 shares of the company’s stock worth $25,000 after acquiring an additional 336 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Hinge Health during the 4th quarter worth about $26,000. CENTRAL TRUST Co purchased a new position in Hinge Health in the 1st quarter valued at about $37,000. First Horizon Corp boosted its stake in shares of Hinge Health by 163.9% during the 4th quarter. First Horizon Corp now owns 855 shares of the company’s stock worth $40,000 after purchasing an additional 531 shares during the last quarter. Finally, High Point Wealth Management LLC purchased a new stake in shares of Hinge Health during the fourth quarter worth about $46,000.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.